Ozempic (semaglutide), a GLP-1 receptor agonist originally designed for type 2 diabetes, has gained widespread attention for its ability to help users lose significant weight.
But what happens when you stop taking it?
Emerging research suggests that the story doesn’t end when the injections do—especially in terms of weight regain.
The Semaglutide Rebound Effect
When semaglutide is discontinued, many users experience what researchers call a “rebound effect”—a reversal of weight loss progress. A key study published in Diabetes, Obesity and Metabolism (2022) found that participants in the STEP 1 trial regained two-thirds of their lost weight within a year of stopping semaglutide. Importantly, their improvements in cardiometabolic risk factors (like blood pressure and blood glucose) also diminished over time.
This rebound isn’t due to withdrawal in a traditional sense, but rather the loss of appetite-suppressing and glucose-regulating effects of the drug. Once semaglutide is removed, hunger typically increases, energy expenditure may drop, and pre-existing habits may resurface.
Real-World Weight Regain
When you stop using Ozempic, the return of appetite and cravings can lead to what’s often referred to as the “Ozempic rebound”—a gradual regain of the weight you previously lost.
A study published in Diabetes, Obesity and Metabolism found that most individuals regained the majority of their lost weight within a year of discontinuing Ozempic or similar medications. This reinforces the understanding that obesity is a long-term, chronic condition that often requires ongoing management.
Importantly, this rebound isn’t exclusive to Ozempic—it can occur with any weight loss method that’s discontinued abruptly.
Long-Term Impact: Is It Sustainable?
While semaglutide is effective, experts now emphasize that long-term use may be necessary to maintain benefits. The American Diabetes Association and Obesity Society recommend that patients view drugs like Ozempic as part of chronic disease management, similar to blood pressure or cholesterol medications.
However, long-term use poses questions about cost, accessibility, and side effects (such as nausea, fatigue, and rare GI complications). Research into lower maintenance doses or tapering protocols is ongoing but remains inconclusive.
Bottom Line
Stopping Ozempic almost always leads to weight regain—how much and how fast depends on multiple factors, including lifestyle, support systems, and whether other treatment strategies are adopted. Clinical trial data show a clear pattern of rebound weight gain within 12 months, while real-world evidence suggests slightly less dramatic, but still significant, regain.
For most patients, GLP-1 therapy should be viewed as a long-term commitment. Lasting success depends not only on pharmacological help but also on ongoing behavioral, nutritional, and psychological support.
Sources & Further Reading:
- Wilding JPH, et al. (2022). Diabetes Obes Metab. https://doi.org/10.1111/dom.14665
- Rubino D, et al. (2021). Lancet. STEP 1 Trial
- Wharton S, et al. (2023). Obesity. Real-world effectiveness of GLP-1s
- American Diabetes Association 2023 Obesity Guidelines
